
A six-month NOVOS Core trial found favorable vascular markers. Here is what the results mean for supplement decisions, travel and active living.

On 2026-11-03, research published in European Heart Journal Open reported favorable vascular findings for NOVOS Core, a multi-ingredient supplement from NOVOS. If you value the freedom to travel and stay active as you age, this is a study worth understanding before changing your routine.
The six-month randomized trial found differences favoring the supplement over placebo in selected measures of blood-vessel function and blood pressure. Those are specific findings with a narrower meaning than the broad promise often attached to the word “longevity.”
For someone weighing another supplement against an already considered health routine, the useful question is straightforward: what did the researchers actually measure, and how much should that influence everyday decisions?
According to the paper, the trial’s primary outcome was flow-mediated dilation, usually shortened to FMD. This is a measure of endothelial function: how well the lining of blood vessels functions. Secondary measures included arterial stiffness and blood pressure alongside blood lipids and an estimated cardiovascular-risk score.
The formulation was selected using prior literature on biological processes associated with aging and vascular dysfunction. The researchers tested whether a combined product aimed at several such processes would produce measurable vascular differences.
That distinction between the product’s rationale and the trial’s measurements matters. The rationale explains why the experiment was conducted. The measured outcomes tell us what the experiment found.
In the STAMINA trial, the authors reported an adjusted FMD difference of 2.9 percentage points favoring NOVOS Core at six months among participants with complete primary-outcome data.
“Adjusted difference” refers to the statistical comparison between the supplement and placebo groups. It should be read as a result from that comparison rather than as the improvement an individual purchaser should expect.
The primary outcome deserves particular attention because it was the main question the trial set out to answer. Here, the result favored the supplement on the researchers’ chosen measure of endothelial function.
The paper reported an adjusted systolic blood-pressure difference of 6.1 mmHg favoring the supplement group at six months. For arterial stiffness, the researchers reported an adjusted pulse-wave-velocity difference of −1.18 m/s.
These findings provide more detail than a general claim that participants became “healthier.” They identify particular measurements that differed between groups. Keeping those measurements visible makes the evidence easier to assess without relying on the product’s longevity positioning.
The University of Surrey described the findings as “encouraging clinical evidence.” Its announcement framed the results as improvements in measures of cardiovascular function, which is the appropriate level at which to read the reported changes.
The authors also reported a modest difference in an estimated 10-year cardiovascular-risk score. The paper explains that the score incorporates conventional risk factors, including systolic blood pressure, and that the difference was driven primarily by the blood-pressure result.
This means the risk-score finding should not be treated as a separate observation of disease prevention. It was a calculation that partly reflected another measured result from the same trial.
For a reader comparing health headlines, this is a useful distinction. A measurement and a prediction based partly on that measurement are related pieces of information, not two independent demonstrations of benefit.
The paper provides several reasons to treat the results as preliminary. These are central to interpreting the trial rather than details to leave until after deciding whether the product appeals.
The trial randomized 61 adults, while the primary complete-case analysis included 43 participants. The headline enrollment therefore does not describe the number contributing complete data to the main analysis.
The study was also small and conducted at a single centre over six months. Its participants were generally healthy non-smoking adults, and the trial excluded some people with relevant health conditions. The authors say the study was not designed to generalize to the wider population or establish effects in a broad higher-risk clinical population.
The trial did not identify which ingredients accounted for the observed changes. It also did not establish whether combining them created additive or synergistic effects, or which biological pathways produced the results.
Nor did it determine whether the measured differences persist beyond the study period. These unanswered questions matter when assessing a multi-ingredient product because evidence for the complete formulation does not automatically explain the contribution of its individual components.
The authors say the trial was not powered to establish whether these intermediate vascular changes translate into fewer cardiovascular events. It did not establish longer life or slower biological aging itself.
The paper calls for longer-term studies with clinical outcomes. Larger and longer research would help clarify whether the observed vascular differences lead to benefits that people experience in their health and daily lives.
The paper reports that NOVOS supplied the study product and matching control, along with an unrestricted research contribution. It also discloses that one author was a NOVOS employee and that the lead academic author had received research funding from NOVOS.
Those relationships do not by themselves settle whether the findings are sound. They are relevant context when evaluating research on a commercial product and deciding how much weight to place on a single trial.
For a ski holiday or a demanding walking trip, the immediate implication is about supplement decisions rather than performance planning. The study’s endpoints provide no tested basis for expecting faster recovery after a flight, easier altitude adjustment or more sustained energy on a hike.
That is the practical boundary between an interesting vascular result and a travel recommendation. A favorable laboratory measure does not tell you how you will feel on the mountain or how much activity to schedule after arrival.
The useful response is therefore modest: keep the finding in its proper decision category. It belongs in a discussion about a particular supplement and its evidence, not in the part of your itinerary that assumes a certain level of recovery or endurance.
If you are considering the product, the research supports discussing its specific ingredients with a qualified clinician alongside your existing medications and health conditions. That keeps the decision tied to your circumstances rather than to the average result in a selected study group.
The review is one practical action. It does not require adopting a complicated supplement schedule or rebuilding an otherwise considered routine around an emerging result.
A selective approach to supplements fits this evidence better than treating every favorable biomarker finding as a reason to add another product. The question is whether the complete formulation has a sensible place in your care, not whether the word “longevity” sounds relevant to your goals.
Questions about aerobic fitness and regular movement remain separate from the supplement question tested here. The same applies to the practical choices involved in planning an active holiday.
For the informed traveler, separating those questions is reassuring. You can take an emerging result seriously without making it responsible for your confidence on a trail or your expectations for a ski day.
The evidence is worth following because it comes from a randomized human trial with specific vascular outcomes. Its appropriate place today is within a considered cardiovascular-health discussion, not as a replacement for established care or a new foundation for adventure planning.
The sensible adjustment is greater selectivity about supplement claims, with any NOVOS Core decision grounded in a clinician-led ingredient review rather than a supplement-led rewrite of your travel and sport routine.
Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.



Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.
explore the Blog